Ethylenediamine tetra acetic acid (EDTA) enhances the antitumor efficacy of cisplatin against human breast cancer cells in vitro | ||
| Egyptian Journal of Cancer and Biomedical Research | ||
| Article 3, Volume 6, Issue 2, June 2022, Pages 23-29 PDF (1013.08 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/jcbr.2022.96763.1233 | ||
| Authors | ||
| Sabry A. El-Naggar1; Yousry El-Bolkiny* 2; Fatheya Makboul Ibrahim3 | ||
| 1Zoology Department, Faculty of Science, Tanta University, Tanta 3111, Egypt | ||
| 2Department of Zoology, Faculty of Science, Tanta University, Egypt | ||
| 3Zoology, Faculty of Science,Suez canal University | ||
| Abstract | ||
| Background: Ethylenediamine tetra acetic acid (EDTA) is used in several biomedical applications. Aim: The aim of this study was to investigate the effect of EDTA treatment on anticancer efficacy of cisplatin (Cis) against human breast cancer (MCF-7) cells in vitro. Materials and Methods:MCF-7 cells were treated either with Cis, EDTA, or their combination for 24h in vitro. The percentages (%) of the inhibitory, and the median inhibitory concentration (IC50) of EDTA were determined by MTT assay. The % of Cis and EDTA on early and late apoptosis, necrosis, and cell cycle of MCF-7 were assessed by flow cytometry. Results: Our data showed slight antitumor effects for EDTA in vitro. However, Cis/EDTA treatment increased the antitumor efficacy of Cis as evidenced by increasing IC50, and the percentage of MCF-7 mortality. Cis/EDTA co-treatment also increased the % of apoptotic and necrotic MCF-7 cells post 24 h of treatment (26.57 and 16.28%, respectively). Furthermore, this co-treatment arrested MCF-7 cell cycle at G0 phase (32.8%) and G2/M phase (30.25%). Conclusion: Co-treatment of EDTA with Cis increased the anticancer efficacy of Cis. | ||
| Keywords | ||
| EDTA; Cisplatin; MCF-7 cells; In vitro; anti-tumor | ||
|
Statistics Article View: 328 PDF Download: 374 |
||
